Skip to Content
Search Menu

ASH | American Society of Hematology Meeting & Exposition

ASH 2025

Alma Månsson

Opposing Roles of LAMA4 in the Bone Marrow Niche During CML

/ Alma Månsson
ASH25CMLLeukemia Play the Video

New Opportunities to Improve Care for People Living with Sickle Cell Disease

/ Jan Andreasen
ASH25
Johan Gustafsson

Towards Identifying Which CLL Patients with Richter Transformation Respond to Immune Checkpoint Inhibitor Therapy

/ Johan Gustafsson
ASH25 Play the Video

Higher-Than-Recommended Lenalidomide Dosing Is Safe in Transplant-Eligible Newly Diagnosed Multiple Myeloma with Renal Impairment

/ Frida Bugge Askeland / Jan Andreasen
ASH25Multiple myeloma

Low-dose Decitabine/Cedazuridine Reduces Toxicity While Preserving Efficacy in Low-risk MDS

/ Jan Andreasen
ASH25
Signe Modvig

Danish Research Identifies Promising New Target for Preventing CNS Relapse in ALL

/ Signe Modvig
ASH25 Play the Video

BPd Preserved or Improved Quality of Life in Patients with RRMM

/ Paul G. Richardson / Jan Andreasen
ASH25Myeloma
Load more

ASH 2025 Highlights – Nordic Webinar

Stay up to date with the most relevant findings and developments presented at ASH 2025. Nordic experts will highlight key clinical data, emerging treatment strategies, and their potential impact on patient care. Join the live session or watch it on demand at your convenience.

ASH 2024

Betty Gardie & François Girdon

LBA-2: A New Cause of Hereditary and Acquired Erythrocytosis

/ Betty Gardie / Francois Girodon
ASH24 Play the Video

Fabian Müller

Treatment of Autoimmune Patients with CD19-CAR T Cells Results in Long-Term Drug-Free Remission or No Progression

/ Fabian Mueller
ASH24CAR-T Play the Video
Alexander Fuglkjær

Machine Learning Can Reduce Unnecessary Hospitalizations for Cancer Patients

/ Alexander Fuglkjær
AIASH24Lymphoma Play the Video
Muhammad Kashif

Novel Risk Stratification Method for Bone Disease in Multiple Myeloma Patients Minimizes Radiation Exposure and Lowers Economic Burden

/ Muhammad Kashif
AIASH24Myeloma Play the Video
Ingrid Glimelius

High Infection Burden and Mortality in CLL Patients: A Call for Action

/ Ingrid Glimelius
ASH24CLL Play the Video
Ingrid Glimelius

Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ASH 2024

/ Ingrid Glimelius
ASH24Lymphoma Play the Video
Ingrid Glimelius

High Mortality Rate for Patients with Mantle Cell Lymphoma with a Second Primary Malignancy

/ Ingrid Glimelius
ASH24Lymphoma Play the Video

AI Will Play a Significant Role in All Aspects of Hematology in the Future

/ Andrew Srisuwananukorn
AIASH24 Play the Video
Mats Jerkeman

Based on Zuma-7 Studies CAR T-Cell Therapy Is Now Standard Treatment for B-Cell Lymphoma in Scandinavia

/ Mats Jerkeman
ASH24B-Cell Lymphoma Play the Video
Meletios-Athanasios Dimopoulos

Daratumumab Monotherapy Shows Clinical Benefit for Early Intervention for Patients with High-Risk Smoldering Multiple Myeloma

/ Meletios A. Dimopoulos
ASH24Myeloma Play the Video
Load more

ASH 2023

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ Hematology / BestPractice Nordic

ASH 2023: FDA Approves Gene Therapies for Sickle Cell Disease

/ Hematology / BestPractice Nordic

ASH 2023: ELEVATE-TN Study - 6-Year Follow-up of Acalabrutinib Efficacy in CLL

/ Hematology / BestPractice Nordic

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

/ Hematology / BestPractice Nordic

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ Hematology / BestPractice Nordic

Hematalogy 2023 • Meet the experts

Get access

2023

Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymphoma Play the Video
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video
Jason Westin

Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

/ Jason Westin
ASH23B-Cell Lymphoma Play the Video
Eva Birgitte Leinøe

Undiagnosed and Unrecognized Patients with a High Bleeding Score

/ Eva Birgitte Leinøe
ASH23 Play the Video
Pieter Sonneveld

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

/ Pieter Sonneveld
ASH23Myelooma Play the Video
Jeff P. Sharman

No increase risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Jeff P. Sharman
ASH23 Play the Video
Gabriel Brisou

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B-Cell Lymphoma

/ Gabriel Brisou
ASH23B-Cell Lymphoma Play the Video
Hamish Scott & Chris Hahn

ERG deficiency syndrome - maybe a new disease

/ Hamish S. Scott / Christopher Hahn
ASH23 Play the Video
Jeff P. Sharman

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

/ Jeff P. Sharman
ASH23CLL Play the Video
Load more

EHA 2026

Follow our coverage of the EHA Congress 2026, where Nordic and international hematology experts share insights on research findings, clinical developments, and new data presented at the congress.

Go to page

Oncology / Hematology • No. 15 • 2023

  • Breast Cancer Focus
  • ESMO 2023
  • Half of Male Lymphoma Survivors Suffer from Erectile Dysfunction
Get access

Latest MEDtalks from ASH 2022

Christine Ryan

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

/ Christine Ryan
ASH22CLL Play the Video
Ryan Jacobs

CLL - The impact of using ibrutinib as front-line treatment

/ Ryan Jacobs
ASH22CLL Play the Video
Eunice Wang

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Eunice Wang
AMLASH22 Play the Video
Roch Houot

Axicabtagene ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients

/ Roch Houot
ASH22Lymphoma Play the Video
Régis Peffault De Latour

Superior efficacy of Iptacopan in PNH patients

/ Régis Peffault De Latour
ASH22 Play the Video
Carsten Utoft Niemann

CLL – Update from ASH 2022

/ Carsten Utoft Niemann
ASH22CLL Play the Video
Load more

Late-Breaking from ASH22 – Let’s Keep the Standard Consolidation Therapy with HDC-ASCT for PCNSL Patients

  • / BestPractice Nordic

Late-Breaking from ASH22 – Zanubrutinib has Now Proven Superiority to Ibrutinib

/ Hematology / BestPractice Nordic

ASH22 – Building Solutions to Challenges in Health Equity

/ Hematology / BestPractice Nordic

ASH 2022 in New Orleans – The Premier Event in Hematology 

/ Hematology / BestPractice Nordic

ASH 2021 abstracts

The ASH Annual Meeting provides several resources on COVID-19 in hematology

/ BestPractice Nordic
ASH21COVID-19
ASH21 poster hall

Long-term remission found with combination therapy for young patients with CLL

/ BestPractice Nordic
ASH21CLL

New prophylactic therapy for patients with hemophilia A and B

/ BestPractice Nordic
ASH21

Polatuzumab vedotin with R-CHP for patients with diffuse large B-Cell lymphoma

/ BestPractice Nordic
ASH21

ZUMA-7: CAR T-cell therapy in earlier lines of therapy benefits patients with relapsed/refractory large B-cell lymphoma

/ BestPractice Nordic
ASH21CAR-TLymphoma

Isatuximab in combination with RVd improves MRD negativity

/ BestPractice Nordic
ASH21Myeloma

ASH 2021 MEDtalks

Promising Preliminary Efficacy in Patients with Relapsed/Refractory Multiple Myeloma

/ Paul G. Richardson
ASH21Myeloma Play the Video
Andrew H. Wei

Maintenance therapy: Oral azacitidine in patients with AML improves long-term overall survival

/ Andrew Wei
AMLASH21 Play the Video
Alexander Fosså

Perspective on the future standard of care for second-line treatment for patients with R/R LBCL

/ Alexander Fosså
ASH21Lymphoma Play the Video
Bjørn Tore Gjertsen

Relapse vaccine is a promising treatment for patients with AML

/ Bjørn Tore Gjertsen
AMLASH21 Play the Video
Manali Kamdar

CAR T Cell Therapy - a new standard of care for 2L treatment of R/R in Large B-cell Lymfoma

/ Manali Kamdar
ASH21Lymphoma Play the Video
Matthew S. Davids

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

/ Matthew S. Davids
ASH21CLL Play the Video
Load more

Order the BestPractice Nordic magazine directly to your address for free.

Register and update your profile here.

Sign up

Onkologia / Hematologia • Nr. 7 • 2021

  • Suolistosyöpäseulonta
  • Syöpäsolujen leviämismekanismit
  • ROR1-reseptori
Get access

Lisää ASH 2020

ASH2020: Early vs Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

/ Aurore Perrot
ASH20 Play the Video

ASH2020: New Treatment Relapsed/Refractory Mantle Cell Lymphoma - data from phase 1 study

/ Maria Lia Palomba
ASH20 Play the Video

ASH2020: DARA to Rd continues to demonstrate a superior PFS benefit

/ Shaji K. Kumar
ASH20 Play the Video

ASH2020: Promising clinical response for CD19-CART-cell therapy in CLL

/ Ohad Benjamini
ASH20 Play the Video

ASH2020: The First-in-Class Anti-CD47 Antibody for AML

/ David A. Sallman
ASH20 Play the Video

ASH2020: Recurrent Crebbp Mutations in Follicular Lymphoma

/ Joe Schroers-Martin
ASH20 Play the Video

ASH2020: Promising results for treatment of AML

/ Tapan M. Kadia
ASH20 Play the Video

ASH2020: Updated efficacy data of maintenance therapy with DARA Plus RVd

/ Jonathan Kaufman
ASH20 Play the Video

Ruxolitinib is a major step forward for patients with chronic GVHD - where corticosteroids are inadequate

/ BestPractice Nordic
ASH20

Subcutaneous Daratumumab in Multiple Myeloma shows reduced the risk of progression or death by 37%

/ BestPractice Nordic
ASH20Myeloma

ASH2020: Promising results for treatment of AML

/ BestPractice Nordic
ASH20Leukemia

ASH2020: Talquetamab, first-in-class bispecific antibody for patients with RRMM

/ Ajai Chari
ASH20Myeloma Play the Video
Mere

Back to top